Anavex Life Sciences Corp (AVXL)

[nidan7500]

If the FDA is allowing multiple trials to start, with the idea that 2-73 can treat multiple indications, and somehow streamline approval, with direction and guidance from the FDA

Agree with your thought process. Almost too good to be true. Suggesting that informed people (medical experts) can review data and actually make a decision on risk to pt. and then actually ACT on the decision. Again, the safety/risk profile of A2-73 is critical at this point, which is probably why Dr. M. has emphasized this so often.

So, let me see if I got your thought process here. A2-73 presents no risk to patient, data suggests efficacy w/Rett (other indications), quickly design a trial to assess efficacy in humans, execute the trial, monitor and measure process/results. Review results according to best clinical practice and cGMP/trials protocol. Can we do that? Binary event day coming. TOGA, TOGA...